Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
Authors:
- J.F. DonohueJDJ.F. Donohue
- M.R. Maleki-YazdiMMM.R. Maleki-Yazdi
- S. KilbrideSKS. Kilbride
- R. MehtaRMR. Mehta
- C. KalbergCKC. Kalberg
- A. ChurchACA. Church
Open Access
- 1 October 2013
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 107 (10) , 1538-1546
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 22 references indexed in Scilit:
- The Efficacy and Safety of the Novel Long-Acting β2 Agonist Vilanterol in Patients With COPDChest, 2012
- A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespiratory Medicine, 2012
- Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax, 2012
- Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrimary Care Respiratory Journal, 2012
- Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD PatientsCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2010
- QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax, 2010
- The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology & Therapeutics, 2010
- Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of AdultsChest, 2010
- Reducing cholinergic constriction: the major reversible mechanism in COPDEuropean Respiratory Review, 2006
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004